Niagen Bioscience Inc

Niagen Bioscience Inc(NAGE)股票分析

$2.105

-0.347 (-16.47%)收盘时

Loading chart…
最高
2.335
开盘
2.320
成交量加权均价
2.16
成交量
1.30M
市值
—
最低
2.050
成交额
2.82M
企业价值/息税折旧摊销前利润(TTM)
23.23

Niagen Bioscience, Inc. is a global bioscience company promoting healthy aging. Its segments include Consumer Products, Ingredients segment, Analytical Reference Standards and Services and Pharmaceuticals. The Consumer Products segment provides finished dietary supplement products that contain its proprietary ingredient, Niagen, directly to consumers and distributors. The ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and outsourcing facilities. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services. The Pharmaceutical segment comprises pharmaceutical development of its proprietary molecules for potential therapeutic applications in rare diseases and conducts research and development activities.

AI 分析 of Niagen Bioscience Inc (NAGE)

持有

Currently, Niagen Bioscience, Inc. (NAGE) is trading at $2.40, significantly below its 52-week high of $7.95, which presents a potential buying opportunity. However, the stock has a low RSI of 38.77, indicating it may be oversold, but it also reflects a lack of strong buying momentum. The forward P/E ratio is 16.67, suggesting that the stock is relatively valued compared to its earnings potential. The main risk is the declining performance in its ingredient business due to increased competition, which could impact future revenue growth.

估值指标

Niagen Bioscience Inc(NAGE)当前预期市盈率为 17.15,5 年平均预期市盈率为 39.86。

预期市盈率

合理
5 年均值 P/E
39.86
当前P/E
17.15
高估
66.13
低估
13.58

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
30.23
当前EV/EBITDA
23.23
高估
43.26
低估
17.20

预期市销率

低估
5 年均值 P/S
3.45
当前P/S
1.22
高估
5.30
低估
1.60

Alphio AI 对 NAGE 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%NAGE

$14.51

情景价格

基

基准

基准 · 50%NAGE

$12.61

情景价格

悲

悲观

悲观 · 25%NAGE

$10.88

情景价格

持有 NAGE 的大户

S

SteelPeak Wealth, LLC

+ 持有NAGE

-5.42%

3个月收益率

事件时间线

2026-11-04 (ET)

16:30:00

Rob Fried: Q3 Revenue $27.2M, Outlook for Growth in 2027

16:30:00

Company Expects E-commerce Revenue Growth of 5%-20% in 2026

2026-10-22 (ET)

09:00:00

Niagen Bioscience Launches Prescription-Only Injection Kit

2026-10-20 (ET)

09:00:00

Niagen Bioscience Launches New Tru Niagen Skincare Category

2026-10-01 (ET)

09:00:00

Niagen Bioscience Launches New Brand Campaign

资讯

NAGE 常见问题 —— 由 Alphio AI 解答

Niagen Bioscience, Inc. is a global bioscience company promoting healthy aging. Its segments include Consumer Products, Ingredients segment, Analytical Reference Standards and Services and Pharmaceuticals. The Consumer Products segment provides finished dietary supplement products that contain its proprietary ingredient, Niagen, directly to consumers and distributors. The ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and outsourcing facilities. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services. The Pharmaceutical segment comprises pharmaceutical development of its proprietary molecules for potential therapeutic applications in rare diseases and conducts research and development activities. It operates in the Healthcare sector.

Currently, Niagen Bioscience, Inc. (NAGE) is trading at $2.40, significantly below its 52-week high of $7.95, which presents a potential buying opportunity. However, the stock has a low RSI of 38.77, indicating it may be oversold, but it also reflects a lack of strong buying momentum. The forward P/E ratio is 16.67, suggesting that the stock is relatively valued compared to its earnings potential. The main risk is the declining performance in its ingredient business due to increased competition, which could impact future revenue growth.

暂无帖子

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易